<DOC>
	<DOCNO>NCT00004682</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether intravenous immunoglobulin effective therapy patient mild moderate myasthenia gravis .</brief_summary>
	<brief_title>Randomized Study Intravenous Immunoglobulin Patients With Mild Moderate Myasthenia Gravis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This study randomize , blind , control study . Patients stratify group accord prior thymectomy ( yes v ) Quantitative Myasthenia Gravis Score ( equal less 10 v great 10 ) equal number assign group . Patients group 2 also stratify whether currently azathioprine . Patients randomize receive either intravenous immunoglobulin ( IVIG ) 2 day 5 % albumin ( placebo ) 2 day . A second infusion IVIG 1 day albumin placebo 1 day give day 22 . At end 6 week , randomize study , patient may choose receive 3 additional IVIG infusion . Patients follow day 1 , 21 , 32 , 42 randomize open label study . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Mild moderate generalize myasthenia gravis Grade 2 3 myasthenia gravis accord modify Osserman group system Ocular myasthenia gravis alone myasthenia gravis crisis eligible Must elevate acetylcholine receptor antibody titer No evidence thymoma chest CT MRI No immunoglobulinA deficiency le 5 mg/dL Group 1 : Patients receive immunosuppressive therapy past , include intravenous immunoglobulin Group 2 : Patients consider steroiddependent Considered steroiddependent demonstrate improvement follow initiation corticosteroid therapy continue generalize weakness examination despite receive 20 mg prednisone ( equivalent ) every day experience unacceptable symptom low dos Prednisone immunosuppressive drug dos must change within last 4 week May immunosuppressive medication ( azathioprine , cyclosporine , cyclophosphamide ) receive plasma exchange treatment initiate 2 month prior study enrollment Must receive immunosuppressive medication least 3 month prior study Prior/Concurrent Therapy Endocrine therapy : Corticosteroid must maintain constant dose study Surgery : No thymectomy last 3 month Other : No plasmapheresis last 2 month Patient Characteristics Age : 15 Weight : No great 80 % ideal body weight Hepatic : SGOT , SGPT , alkaline phosphatase great 1.5 time upper limit normal ( ULN ) Renal : BUN great ULN Creatinine great ULN Neurology : No history relevant chronic degenerative , psychiatric , neurologic disorder , myasthenia gravis , produce weakness fatigue No alter consciousness , dementia , abnormal mental status Pulmonary : Forced vital capacity least 50 % predict Not high risk aspiration Other : No active thyroid gland dysfunction manifest abnormal thyroid function test need current thyroid replacement Normal thyroid function test require No major relevant chronic debilitating illness within 6 month study Not pregnant nurse Adequate contraception require fertile patient</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>myasthenia gravis</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>